AstraZeneca received more than $1 billion funding from the U.S. government for expanding the manufacturing of an experimental coronavirus vaccine from the University of Oxford.
The U.K.-based company said it received the amount from the U.S. Biomedical Advanced Research and Development Authority for the development, production, and delivery of the vaccine. The vaccine is being developed by Oxford and the U.K. government.
The development includes a phase 3 clinical trial consisting of 30,000 participants and a pediatric trial.
AstraZeneca has secured a total manufacturing capacity for 1 billion doses.